Results 11 to 20 of about 16,920 (213)

Design of a Protein with Improved Thermal Stability by an Evolution‐Based Generative Model

Angewandte Chemie, Volume 134, Issue 50, December 12, 2022., 2022
Protein design bears great interest in both research and industry. Evolutionary‐based methods have been promising in designing new sequences based on the concept that the evolutionary fitness of a sequence is closely related to folding stability. Here we present a computational pipeline that, thanks to a combination of sequence‐ and structure‐based ...
Pengfei Tian, Adrien Lemaire, Fabien Sénéchal, Olivier Habrylo, Viviane Antonietti, Pascal Sonnet, Valérie Lefebvre, Frederikke Isa Marin, Robert B. Best, Jérôme Pelloux, Davide Mercadante   +10 more
wiley   +2 more sources

Prevalence of radiotherapy, chemotherapy and access to supportive care in cancer in Brazil, China, France, Russia and the USA

European Journal of Cancer Care, Volume 31, Issue 6, November 2022., 2022
Abstract Objectives The objective of this study is to assess the prevalence of treatment with radiotherapy and/or chemotherapy in the general adult population of five countries (Brazil, China, France, Russia and the USA) and to evaluate the use of different Supportive Care in Cancer (SCC) services. Methods A total of 11,100 individuals representing the
Guillaume Buiret, Véronique Delvigne, Guénaëlle le Dantec, Pascale Guyonnet‐Debersac, Charles Taïeb   +4 more
wiley   +1 more source

Omalizumab for successful chemotherapy desensitisation: What we know so far

Clinical and Translational Allergy, Volume 11, Issue 10, December 2021., 2021
Abstract Background Hypersensitivity reactions induced by chemotherapeutic drugs may influence the course of the oncologic disease by preventing doctors from prescribing first‐line therapy. In order to prevent another hypersensitivity reaction to the culprit chemotherapeutic agent, the physician can decide between two possibilities: premedication or ...
Roxana Silvia Bumbacea, Selda Ali, Sabina Loredana Corcea, Luiza Spiru, Cornelia Nitipir, Victor Strambu, Dragos Bumbacea   +6 more
wiley   +1 more source

PF385 ANTICOAGULATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH IBRUTINIB

HemaSphere, Volume 3, Issue S1, Page 144-145, June 2019., 2019
Background: Ibrutinib therapy is associated with an increased risk of bleeding due to a currently poorly understood effect on multiple platelet signaling pathways, with up to 35% of patients experiencing bleeding events on ibrutinib therapy (Brown; Br J Hem 2019).
W.J. Archibald, W. Ding, T.G. Call, K.G. Rabe, A.B. Koehler, N.E. Kay, S.S. Kenderian, J.F. Leis, B.F. Kabat, S.M. Schwager, A.L. Fonder, S.L. Slager, E. Muchtar, S.A. Parikh   +13 more
wiley   +1 more source

PF386 HYPERTENSION IN PATIENTS TREATED WITH IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

HemaSphere, Volume 3, Issue S1, Page 145, June 2019., 2019
Background: Hypertension (HTN) is the most common grade ≥ 3 Ibrutinib (Ibr)‐associated adverse event (AE) observed in clinical trials (26%) (O’Brien, Blood 2015). Meta‐analysis of clinical trial data suggests a 2.8‐fold increased risk of HTN for patients (pts) treated with Ibr vs. placebo (Caldeira, PLOS ONE 2019).
L. Roeker, M. Yazdy, L. Gashonia, J. Goodfriend, M. Narkhede, J. Rhodes, K. Kennard, H. Morse, C. Dorsey, K. Battiato, M. Peterson, J. Carver, S. Schuster, B. Cheson, A. Mato   +14 more
wiley   +1 more source

PF387 FRENCH IBRUTINIB OBSERVATIONAL STUDY (FIRE): REAL‐WORLD STUDY OF IBRUTINIB TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN FRANCE

HemaSphere, Volume 3, Issue S1, Page 145-146, June 2019., 2019
Background: Ibrutinib is a first‐in‐class oral inhibitor of Bruton's tyrosine kinase approved for the treatment of adult patients (pts) with CLL. Single‐agent ibrutinib improved progression‐free survival (PFS) and overall survival (OS) vs chlorambucil in treatment‐naïve pts (RESONATE‐2™; NCT01722487; Burger et al. N Engl J Med.
C. Dartigeas, P. Feugier, L. Ysebaert, M.‐S. Dilhuydy, A. Delmer, S. Tardy, B. Anglaret, L. Voillat, K. le DÛ, B. Slama, C. Albrecht, L. Jenayah, S. Beauclair, R. Wapenaar, C. Kavanagh, V. Leblond   +15 more
wiley   +1 more source

PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

HemaSphere, Volume 3, Issue S1, Page 577-578, June 2019., 2019
Background: Lenalidomide plus rituximab (R2) has established efficacy and a tolerable safety profile in patients with previously untreated and relapsed/refractory (R/R) indolent NHL. This includes patients with marginal zone lymphoma (MZL) who are generally treated in a similar manner to follicular lymphoma (FL).
C. Thieblemont, J.P. Leonard, M. Trneny, K. Izutsu, N.H. Fowler, X. Hong, H. Zhang, F. Offner, A. Scheliga, G. Nowakowski, A. Pinto, F. Re, L.M. Fogliatto, P. Scheinberg, I. Flinn, C. Moreira, M. Czuczman, S.A. Kalambakas, P. Fustier, C. Wu, J. Gribben   +20 more
wiley   +1 more source

De l'inefficacité du réseau social : des liens sociaux non mobilisés chez les patients atteints de cancer [PDF]

, 2014
International audienceDe nombreuses études sur les réseaux sociaux portent sur la question des ressources auxquelles un individu peut avoir accès à travers ses relations sociales.
Bourdieu P, Caplan GA, Coser RL, Degenne A, Ferrand A, Fédération Nationale des Etablissements d’Hospitalisation A Domicile (FNEHAD), Granovetter M, Institut national du cancer (INCa), Le Queau P, Ménoret M, Nabarette H, Petite S   +11 more
core   +3 more sources

PS1263 CONSOLIDATION THERAPY USING 90Y‐IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012)

HemaSphere, Volume 3, Issue S1, Page 578, June 2019., 2019
Background: The role of consolidation therapy with 90Y‐ibritumomab tiuxetan (90YIT) for patients with follicular lymphoma (FL) after receiving second or third line immunochemotherapy has not been established. Aims: Thus, we conducted a multicenter phase II trial evaluating the efficacy and toxicities of bendamustine and rituximab (BR) followed by 90YIT
H. Tsujimura, K. Miura, M. Kanno, Y. Masaki, M. Iino, J. Takizawa, Y. Maeda, K. Yamamoto, S. Tamura, A. Yoshida, H. Yagi, I. Yoshida, K. Kitazume, T. Matsunari, I. Choi, Y. Kakinoki, T. Yoshino, S. Nakamura, T. Yoshida   +18 more
wiley   +1 more source

PS1264 FRENCH IBRUTINIB OBSERVATIONAL STUDY (FIRE): REAL‐WORLD STUDY OF IBRUTINIB TREATMENT FOR MANTLE CELL LYMPHOMA (MCL) IN FRANCE

HemaSphere, Volume 3, Issue S1, Page 578-579, June 2019., 2019
Background: Ibrutinib is a first‐in‐class oral inhibitor of Bruton's tyrosine kinase approved for the treatment of adult patients (pts) with MCL who have received ≥1 prior therapy (R/R). In registrational clinical trials (Study 1104 [NCT01236391]; Wang et al. Blood. 2015;126:739–745; MCL3001 [NCT01646021]; Dreyling et al. Lancet.
B. Slama, A. Delmer, G. Cartron, B. Anglaret, O. Fitoussi, K. le DÛ, L. Oberic, F. Peyrade, H. Orfeuvre, D. Senecal, L. Molina, C. Albrecht, J. Thevenon, S. Beauclair, C. Kavanagh, S. Le Gouill   +15 more
wiley   +1 more source